Allogeneic hematopoietic cell transplantation for patients with AML aged 70 years or older in first remission. A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)
Standard
Allogeneic hematopoietic cell transplantation for patients with AML aged 70 years or older in first remission. A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). / Maffini, Enrico; Ngoya, Maud; Galimard, Jacques-Emmanuel; Harbi, Samia; Kröger, Nicolaus; Platzbecker, Uwe; Sengeloev, Henrik; Craddock, Charles; Potter, Victoria; Choi, Goda; Chevallier, Patrice; Stölzel, Friedrich; Tholouli, Eleni; Maertens, Johan; Ciceri, Fabio; Cornelissen, Jan; Sanz, Jaime; Spyridonidis, Alexandros; Lanza, Francesco; Nagler, Arnon; Mohty, Mohamad.
in: BONE MARROW TRANSPL, Jahrgang 58, Nr. 9, 09.2023, S. 1033-1041.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Allogeneic hematopoietic cell transplantation for patients with AML aged 70 years or older in first remission. A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)
AU - Maffini, Enrico
AU - Ngoya, Maud
AU - Galimard, Jacques-Emmanuel
AU - Harbi, Samia
AU - Kröger, Nicolaus
AU - Platzbecker, Uwe
AU - Sengeloev, Henrik
AU - Craddock, Charles
AU - Potter, Victoria
AU - Choi, Goda
AU - Chevallier, Patrice
AU - Stölzel, Friedrich
AU - Tholouli, Eleni
AU - Maertens, Johan
AU - Ciceri, Fabio
AU - Cornelissen, Jan
AU - Sanz, Jaime
AU - Spyridonidis, Alexandros
AU - Lanza, Francesco
AU - Nagler, Arnon
AU - Mohty, Mohamad
N1 - © 2023. The Author(s), under exclusive licence to Springer Nature Limited.
PY - 2023/9
Y1 - 2023/9
N2 - Accessibility to allogeneic hematopoietic cell transplantation (HCT) programs for older patients is growing constantly. We report on the clinical outcomes of a group of 701 adults aged ≥70 years, with acute myeloid leukemia (AML) in first complete remission (CR1), who received a first HCT, from HLA-matched sibling donors (MSD), 10/10 HLA-matched unrelated donors (UD), 9/10 HLA-mismatched unrelated donors (mUD) or haploidentical (Haplo) donors. The 2-year overall survival (OS) was 48.1%, leukemia-free survival (LFS) 45.3%, relapse incidence (RI) 25.2%, non-relapse mortality (NRM) 29.5% and GVHD-free, relapse-free survival (GRFS), 33.4%. Compared to MSD, patients transplanted from Haplo and UD presented lower RI (HR 0.46, 95% CI 0.25-0.8, p = 0.02 and HR 0.44, 95% CI: 0.28-0.69, p = 0.001, respectively); this translated into prolonged LFS for Haplo (HR 0.62, 95% CI: 0.39-0.99, p = 0.04). Patients transplanted from mUD exhibited the highest NRM incidence (HR 2.33, 95% CI: 1.26-4.31, p = 0.007). HCT in selected adult CR1 AML patients >70 years is feasible and could be associated with good clinical outcomes. Prospective clinical trials are warranted.
AB - Accessibility to allogeneic hematopoietic cell transplantation (HCT) programs for older patients is growing constantly. We report on the clinical outcomes of a group of 701 adults aged ≥70 years, with acute myeloid leukemia (AML) in first complete remission (CR1), who received a first HCT, from HLA-matched sibling donors (MSD), 10/10 HLA-matched unrelated donors (UD), 9/10 HLA-mismatched unrelated donors (mUD) or haploidentical (Haplo) donors. The 2-year overall survival (OS) was 48.1%, leukemia-free survival (LFS) 45.3%, relapse incidence (RI) 25.2%, non-relapse mortality (NRM) 29.5% and GVHD-free, relapse-free survival (GRFS), 33.4%. Compared to MSD, patients transplanted from Haplo and UD presented lower RI (HR 0.46, 95% CI 0.25-0.8, p = 0.02 and HR 0.44, 95% CI: 0.28-0.69, p = 0.001, respectively); this translated into prolonged LFS for Haplo (HR 0.62, 95% CI: 0.39-0.99, p = 0.04). Patients transplanted from mUD exhibited the highest NRM incidence (HR 2.33, 95% CI: 1.26-4.31, p = 0.007). HCT in selected adult CR1 AML patients >70 years is feasible and could be associated with good clinical outcomes. Prospective clinical trials are warranted.
KW - Aged
KW - Humans
KW - Acute Disease
KW - Bone Marrow
KW - Hematopoietic Stem Cell Transplantation/adverse effects
KW - Leukemia, Myeloid, Acute
KW - Prospective Studies
KW - Recurrence
KW - Retrospective Studies
KW - Transplantation Conditioning
KW - Unrelated Donors
KW - Graft vs Host Disease
U2 - 10.1038/s41409-023-02027-y
DO - 10.1038/s41409-023-02027-y
M3 - SCORING: Journal article
C2 - 37386253
VL - 58
SP - 1033
EP - 1041
JO - BONE MARROW TRANSPL
JF - BONE MARROW TRANSPL
SN - 0268-3369
IS - 9
ER -